Hybridize Pharma

Who we are


We are a pre-clinical stage biotech company that spun-out from the Leiden University Medical Center in 2019. We are an R&D performing SME, creating value by developing RNA-based therapeutics that specifically target viruses that become reactivated under immunosuppression. We have the ambition to become a global player in developing anti-viral therapies.

READ MORE

Hybridize Pharma’s mission


Our mission is to develop innovative RNA-based therapeutics that specifically target viruses.

Our Pipeline

Watch here, the interview with the Nierstichting about HYB-BKV.


Latest Publication


‘We waren verrast toen dit idee bleek te werken’

Source nemokennislink.nl

Read article